Treatment with the neutralizing anti-TNFSF14 antibody led to a similar improvement in survival and weight loss (Figure 7, F and G), supporting the hypothesis that post-influenza TR-AM maintenance is key to survive secondary pneumococcal infection. The gene discussed is TNFSF14; the disease is pneumococcal infection.